Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

The Department of Health and Human Services (HHS), Office of Minority Health requests that the National Academies of Sciences, Engineering, and Medicine convene an ad hoc committee to develop a ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

LMP Capital and Income Fund offers an 8% dividend yield, focusing on income through diverse investments in MLPs, REITs, and common stocks. SCD's strategy includes a mix of energy and tech stocks, ...

Sickle cell disease (SCD) is a pressing global health issue, with rising cases and mortality, especially in low- and middle-income countries (LMICs). Hydroxyurea, a cost-effective treatment for SCD, ...